Adicet Bio Inc Stock News

Adicet Bio, Inc. (ACET) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $0.56 per share a year ago.

Adicet Bio, Inc. (ACET) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to earnings of $0.10 per share a year ago.

While the concept of high-risk speculation seems particularly dangerous at this juncture, gamblers may nevertheless want to consider the merits of targeting potentially lucrative biotech stocks that c

Biotechs developing CAR-T cell therapies have seen their valuations plummet in 2022 - making them an intriguing speculative buy opportunity in 2023. This is a complex field characterized by study fail

Here is how Adicet Bio, Inc. (ACET) and AlloVir, Inc. (ALVR) have performed compared to their sector so far this year.

Adicet Bio, Inc. (ACET) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in r

Adicet Bio (ACET), Enfusion (ENFN), Dillard's (DDS), First BanCorp. (FBP) and Hillenbrand (HI) could bring gifts of surprise returns from Secret Santa.

Adicet Bio, Inc. (ACET) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings es

The stock price of Adicet Bio (ACET) plummeted over 35% intraday today. This is why.

Adicet Bio's Inc. ACET, -13.13% stock tumbled about 38% in premarket trading on Monday after the company shared data from a Phase 1 clinical trial evaluating the company's investigational CAR-T therap

Here is how Adicet Bio, Inc. (ACET) and Merck (MRK) have performed compared to their sector so far this year.

Adicet Bio, Inc. (ACET) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

REDWOOD CITY, Calif. & BOSTON--( BUSINESS WIRE )--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer,

REDWOOD CITY, Calif. & BOSTON--( BUSINESS WIRE )--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer,

Here is how Adicet Bio, Inc. (ACET) and RxSight, Inc. (RXST) have performed compared to their sector so far this year.